Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Alejandro Medina, Noemi Puig, Juan Flores-Montero, Cristina Jimenez, M.-Eugenia Sarasquete, Maria Garcia-Alvarez, Isabel Prieto-Conde, Carmen Chillon, Miguel Alcoceba, Norma C. Gutierrez, Albert Oriol, Laura Rosinol, Joan Blade, Mercedes Gironella, Miguel T. Hernandez, Veronica Gonzalez-Calle, Maria-Teresa Cedena, Bruno Pavia, Jesus F. San-Miguel, Juan-Jose Lahuerta, Maria-Victoria Mateos, Joaquin Martinez-Lopez, Alberto Orfao, Marcos Gonzalez and Ramon Garcia-Sanz

Abstract
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high ($R^2 = 0.905$). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; $p < 0.001$ for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, $p < 0.01$ for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45, $p < 0.001$) and OS (HR: 0.21, 95% CI: 0.06–0.75, $p = 0.02$). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.

Introduction
Multiple myeloma (MM) is a B-cell malignancy where plasma cells arise from a single clone accumulated in the bone marrow, and usually produce monoclonal immunoglobulins (M-protein or monoclonal component). New agents such as proteasome inhibitors and immunomodulatory drugs, together with autologous stem cell transplantation (ASCT) have increased the proportion of patients achieving complete response (CR) in this disease, which has been translated into better progression-free survival (PFS) and overall survival (OS) rates during the last 10 years. This improvement led to the definition of new response categories (i.e. stringent complete response, sCR), but even myeloma patients with such good responses still relapse due to the presence of residual tumor cells in the bone marrow (i.e. minimal residual disease, MRD) that remain undetectable by conventional serological and morphological methods. New methods are capable of detecting MRD with a higher prediction ability, since negative patients had longer survival rates compared to positive patients.
even when only patients in CR are considered. Accordingly, the International Myeloma Working Group (IMWG) developed new criteria to define MRD negative responses, characterized by the absence of clonal malignant plasma cells in patients with suspected CR, assessed with a sensitivity of at least $10^{-5}$—one malignant cell per hundred thousand normal cells; therefore, only very sensitive and reliable methods can be applied to detect MRD.

Nowadays, MRD in MM can be studied using two different approaches: immunophenotypic (multiparametric flow cytometry, MFC) and molecular techniques (next-generation sequencing —NGS—, digital PCR). Imaging tools (PET-CT, MRI) can add some extra information in terms of prognostic evaluation, however, standardized procedures to perform MRD assessment in myeloma have only been developed for MFC and NGS. Despite the added value for MRD assessment, next-generation strategies are currently used only in a few centers and usually limited to the context of clinical trials.

MFC allows the identification and quantification of abnormal plasma cells based on an aberrant protein-marker expression profile displayed by myeloma cells. Recently, the EuroFlow consortium has developed a two-tube, eight-color flow assay that allows the simultaneous analysis of up to 10 million cells (next-generation flow, NGF); NGF has been already approved by the IMWG as a reference method to detect and define immunophenotypic CRs in MM. NGF reaches a sensitivity of $2 \times 10^{-6}$, overcoming previous flow protocols ($10^{-4}$–$10^{-5}$), but it is highly dependent on the precise identification of the pathologic immunophenotype, requiring a high level of expertise; in addition, the quality of the sample must be high and should be promptly processed.

Molecular methods use the clonal immunoglobulin gene rearrangement as target for the detection of MRD levels. Quantitative PCR uses allele-specific oligonucleotides targeting the junction region of the immunoglobulin genes; it has been extensively used as the molecular gold-standard approach to detect MRD levels in lymphoid malignancies. Nonetheless, it is a labor-intensive technique, requiring the construction of a standard curve for every single patient, and its applicability accounts only for 40–75% of myeloma patients. By contrast, NGS strategies have been rapidly introduced in the clinical setting, especially for myeloma. However, the only strategy approved by the IMWG and cleared by the FDA — Adaptive’s clonoSEQ™— is not commercially available, and its cost makes it unaffordable for most centers.

We aimed at validating the potential applicability and usefulness of a new NGS methodology for the diagnosis and MRD detection in MM patients. To that end, we have evaluated a commercial NGS panel, LymphoTrack®, in a cohort of 106 myeloma patients, and compared the results with NGF.

### Materials and methods

#### Patient and sample selection

Patient selection was based on the following criteria: (i) newly diagnosed MM, transplant-candidate patients included in the Spanish GEM2012 clinical trial, whose clonotypic rearrangements were previously identified, (ii) NGF evaluation performed at diagnosis and follow-up per protocol, and (iii) enough amount of gDNA available for MRD studies. Bone marrow samples from eligible MM patients were collected at day 100 following transplantation: two independent pulls were obtained and subsequently processed to perform flow and molecular studies.

Patients with t(4;14), t(14;16), or del17p by FISH were grouped together in a high-risk cytogenetic subgroup according to the IMWG criteria. The revised international staging system (R-ISS) was also applied to stratify patients according to the ISS stage, serum LDH, and cytogenetics. The study was conducted in accordance with Declaration of Helsinki principles, was approved by the Committee of the University Hospital of Salamanca, and written informed consent was required and obtained from each patient prior to their inclusion.

#### DNA extraction and quantification

gDNA was isolated from bone marrow aspirates of newly diagnosed MM patients using the automated DNA Purification kit Maxwell® (Promega, Madison, WI, USA). gDNA quality was first assessed using NanoDrop2000 (ThermoFisher, Waltham, MA, USA). Samples were quantified using Qubit 2.0 and the dsDNA BR assay (ThermoFisher, Waltham, MA, USA).

To improve the quality of follow-up samples, those with insufficient DNA concentration for MRD purposes (i.e. those with <100 ng/µl) were ethanol-precipitated. To do this, 1/10 volume sodium acetate, as well as twice the sample volume of 100% ethanol (stored at −20°C) were added to the samples and incubated overnight at −20°C. Afterwards, samples were centrifuged at 17,900 × g and 4°C for 10 min. The nucleic acid pellet was then washed with 500 µl ethanol (70%) and centrifuged again at 17,900 × g and 4°C for 5 min. Finally, the pellet was dried and rehydrated in ≈12 µl of water, and quantified using the Qubit dsDNA BR assay.

#### Gene amplification and sequencing

The LymphoTrack® IGH panel (Invivoscribe Technologies, San Diego, CA, USA) was used for the analysis of MRD samples to detect previously characterized clonotypic rearrangements of the immunoglobulin heavy chain loci (IGH). Clonal rearrangements were first determined in matched baseline samples by PCR amplification and Sanger sequencing using the BIOMED-2 primers as previously described.
Briefly, this commercial NGS strategy uses primers targeting the immunoglobulin framework regions in order to amplify V(D)J rearrangements. In one-step PCR (Fig. S1) amplicons are generated and one-side indexed, allowing the simultaneous sequencing of up to 24 samples in a single run. Whenever possible, ≥650 ng of DNA were used to reach a sensitivity level of at least $10^{-5}$ (assuming 6.5 pg of DNA per cell, input for NGS would be at least 100,000 cells). In addition, DNA from one clonal, well-characterized B cell line was added in each reaction as a control spike-in (corresponding to 100 cells), to allow the absolute quantification of tumor plasma cells.

After a purification step with Agentcourt AMPure XP microbeads (Beckman Coulter Inc., Brea, CA, USA) and 70% ethanol, and purity and quantity assessment using the TapeStation 4200 (Agilent, Santa Clara, CA, USA) and KAPA library quantification kit (KAPA Biosystems, Boston, MA, USA) or Qubit 2.0, respectively, ampiclon libraries of 12–20 pM were prepared. These libraries were later sequenced in a MiSeq platform (Illumina, San Diego, CA, USA) using v3 reagent kits and $2 \times 251$ sequencing cycles, aiming at one million reads per sample.

**Sequence analysis and MRD evaluation**

Resulting FastQ files were processed using the LymphoTrackAnalysis® software and the LymphoTrack® MRD Data Analysis tool 1.1.0 (Inivivscirbe Technologies) to retrieve sequences from virtually every clonal B cell of the samples. This allowed the identification of residual tumor cells, if present, by tracking their clonotypic IGH complementarity-determining region 3 (CDR3) that had previously been characterized. The software performs a calculation considering the number of spike-in cells used for each reaction, as well as tumor and spike-in read counts. Sequencing results were considered invalid when <20,000 total reads were obtained. A sample was considered positive for MRD assessment when at least two identical clonotypic reads were detected; conversely, a sample was considered negative (undetectable) for MRD when criteria for positivity were not met. Vidjil (University of Lille) and Arrest/Interrogate (EuroNGS) tools were also used to analyze FastQ files from MRD sequencing.

In order to make comparisons, patients were eventually classified into different groups according to the MRD status (MRD-positive and MRD-negative), the MRD level (MRD-negative, MRD-positive below $10^{-5}$, MRD-positive between $10^{-5}$ and $10^{-4}$, and MRD-positive higher than $10^{-3}$), the conventional response (VGPR/PR and sCR/CR), and the cytogenetic risk (high- and standard-risk).

**MFC studies**

Follow-up samples were processed within 24 h after collection. Analysis was carried out using the recently developed NGF methodology (Table S1), following the EuroFlow guidelines, as described elsewere. Events from two eight-color tubes (per sample) were merged using the merge function of the INFINICYT™ v2.0 software (Cytognos S.L. Salamanca, Spain). A sample was considered positive when at least 20 aberrant plasma cells were detected. Hemodilution of bone marrow samples for NGF evaluation was assessed through the identification of a significant decrease in non-plasma cell populations: mast cells (CD117hi), erythroblasts (CD45−/sideward-scatterlo) and B-cell precursors (CD19+/CD38hi/CD45lo). The complete analysis of NGF performance for the GEM2012 trial has already been published.

**Statistical analysis**

Patients’ characteristics were analyzed with the SPSS 23.0 software (IBM, Armonk, NY, USA) using Fisher’s exact test for discrete variables and the Mann–Whitney test for continuous variables. Bland–Altman plots were used to test the potential agreement between methods. The Kaplan–Meier method and the log-rank test were used to plot and compare PFS and OS curves. Cox regression was used to perform univariate and multivariate analyses. By Landmark analysis, only those patients who had not progressed or died on day 100 post ASCT were evaluated. PFS was defined as the time from MRD assessment to the last follow-up visit, disease progression or death by any cause. OS was defined as the time from MRD assessment to the last follow-up visit or patient’s decease by any cause. All reported $p$ values were obtained by a two-sided exact method, at the conventional 5% significance level ($p < 0.05$).

**Results**

**Patient characteristics**

One hundred and six (106) patients met the inclusion criteria. Clinical variables of our cohort are described in Table S2. Median age at diagnosis was 59 years. Male to female proportion was 58/42. Patients with high-risk cytogenetics represented 22.5% of the present series [$n = 23/102$, one of them with t(4;14) plus del17p]. The R-ISS stages I, II, and III represented 25.2%, 59.2%, and 15.5% of patients, respectively. After a median follow-up of 39.5 months from MRD assessment (interquartile range: 33.8–46.2 months), 31 patients had relapsed (29.2%) and 16 had died (15.1%), two of them without progression, due to infections.

At the corresponding MRD evaluation time point, the overall response rate was 96.2%: 32.1% of patients achieved sCR, 23.6% CR, 34.0% very good partial response (VGPR) and 6.6% partial response (PR). Only four patients (3.8%) had stable/progressive disease (SD/PD). Three-year PFS and OS rates were 72.5% and 86.7%, respectively.
Comparison of NGS and NGF performance

Sample quality and ethanol precipitation were the main variables affecting NGS applicability for MRD analysis. Because of that, the minimum number of cell equivalents required to perform the studies was 2 x 10^5 cells. Considering NGF, 3-year OS rates of negative and positive patients were 96.2% and 77.3%, respectively (Fig. 3A; p < 0.01). As it is shown in Fig. 1A, we found a good correlation between methods (r = 0.951; R^2 = 0.905), with 15 discordant cases (5 NGF+/NGS--; 10 NGF--;NGS+). It is worth mentioning that the majority of NGS-only MRD-positive cases (7/10) presented values below 10^-5, while this situation was found in two out of five NGF-only MRD-positive cases. Bland–Altman analysis demonstrated an excellent level of agreement between NGS and NGF (Fig. 1B).

Characteristics of patients with undetectable MRD who had disease progression

Table 1 Cell input for NGS- and NGF-based MRD studies.

| Input cells | NGS | NGF |
|-------------|-----|-----|
| <10^5       | 10.4%a | 0% |
| 10^5 – 2 x 10^5 | 32.1% | 0% |
| >2 x 10^5 | 57.5% | 100% |
| >10^6       | 0% | 100% |

Median cell input: 210,672 [Interquartile range: 136,382–264,110] NGF vs. NGS: 9,200,276 [5,702,369–10,305,207]. Median sensitivity: NGS 10^-5, NGF 2 x 10^-6. Cell input range: 3542–726,264, 1,548,175–15,000,000.

Table 2 MRD stratification for next-generation flow and next-generation sequencing.

| MRD level | Current study | GEM2012 |
|-----------|---------------|---------|
|            | NGS           | NGF     | NGF     |
| Negative  | 53 (50.0%)    | 58 (54.7%) | 173 (54.6%) |
| <10^-5    | 16 (15.1%)a   | 9 (8.5%)  | 18 (5.7%)a |
| ≥10^-5 and <10^-4 | 17 (16.0%) | 21 (19.8%) | 65 (20.9%) |
| ≥10^-4    | 20 (18.9%)    | 18 (17.0%) | 61 (19.2%) |
| Total     | 106           | 106      | 317      |

MRD results, obtained using NGS or NGF, were compared for the 106 patients in our cohort. Results obtained in the GEM2012 Spanish trial (7) (intent-to-treat population) were used as a reference. Absolute numbers and percentage (in parenthesis) for each MRD category are shown in each cell. The minimum number of cell equivalents was 2 x 10^5 cells. Considering NGF, 3-year OS rates of negative and positive patients were 96.6% and 74.9%, respectively (Fig. 3B; p < 0.01). There were no statistical differences in PFS between NGS and NGF analysis. Fisher’s exact test showed statistical differences in the proportions of each subgroup (two-sided p = 0.004).

Intermediate ISS status and LDH was normal. Of note, two of these patients had extramedullary disease (one already present at diagnosis), while another one relapsed after more than 3 years in sustained MRD negativity, one year following their treatment suspension. The other two patients had conventional disease progressions ~36 months after transplantation.

Undetectable MRD was clinically significant by NGS and NGF

Negative patients showed a significantly better 3-year PFS rate than positive patients (p < 0.001), either basing on NGS or NGF results (88.7% vs. 56.6%; 91.4% vs. 50%, Fig. 2A and B, respectively, p < 0.001). Three-year OS rates were very high for all subgroups: considering NGS, 3-year OS rates of negative and positive patients were 96.2% and 77.3%, respectively (Fig. 3A; p < 0.01). Considering NGF, 3-year OS rates of negative and positive patients were 96.6% and 74.9%, respectively (Fig. 3B; p < 0.01). There were no statistical differences in PFS between double-negative and discordant cases (36-month PFS: 91.7% and 80%, respectively, p = 0.55, Fig. S2), while both subgroups had significantly better PFS rates than double-negative cases (median PFS: 34.2 months, p < 0.05 for both comparisons).

Moreover, survival rates progressively increased from patients with high-positive MRD to patients with undetectable residual disease (Fig. S3): by NGS, 36-month PFS rates of ≥10^-3, 10^-5 – 10^-4, <10^-5 and negative groups were 55%, 52.9%, 62.5%, and 88.7%, respectively (p < 0.01). By NGF, they were 38.9%, 47.6%, 77.8%, and 91.4%, respectively (p < 0.001). OS rates of these subsets followed the same trend.
MRD overcomes response-to-treatment and cytogenetics as a predictive factor

As in prior reports, we correlated the MRD status with different clinical variables such as heavy and light chains usage, ISS, R-ISS, cytogenetics, and conventional response. We only detected a significant association between achieving CR/sCR and MRD negativity (Fig. S4). Thus, by NGS we observed that 71.2% of patients in CR/
sCR were MRD negative, while only 23.3% of patients in VGPR/PR achieved MRD negativity (p < 0.0001); when NGF data were used, 81.4% of patients in CR/sCR were MRD-negative versus only 20.9% of patients in VGPR/PR (p < 0.0001). No differences were observed in the proportion of each group when both techniques were compared (p > 0.05).

A significant relationship between negative MRD and longer PFS was observed irrespective to the response (Fig. S5) when patients achieving at least VGPR were considered (n = 95). Remarkably, MRD-negative patients achieving VGPR showed comparable 3-year PFS rates to those achieving CR or sCR; this result was similar either considering NGS (VGPR: 88.9%, CR/sCR: 88.1%; p > 0.05) or NGF data (VGPR: 100%, CR/sCR: 89.6%; p > 0.05). On the other hand, MRD-positive patients had inferior outcomes, with no differences observed between responses.

Then, we stratified patients (n = 102) into four groups considering the MRD status (positive or negative) and cytogenetics (high-risk or standard-risk). MRD-negative patients showed excellent 3-year PFS rates independently of their cytogenetic status (Fig. S6), while the outcome of MRD-positive patients was significantly determined by their cytogenetic profile: 3-year PFS rates were prolonged for standard-risk patients (67.1% by NGS, 61.8% by NGF), while for high-risk patients it was 28.6% by NGS and 15.4% by NGF (median PFS: 14.5 months by NGS and 12.8 months by NGF, p < 0.01 compared to the other groups). For OS (Fig. S7), all MRD-negative patients showed comparable 3-year survival rates to those patients showing MRD positivity but no high-risk cytogenetic alteration (OS rates >90% for all categories, p > 0.05 for all paired comparisons); conversely, survival rates of high-risk, MRD-positive patients were significantly lower than the other subgroups (median OS: 21.7 months for NGS and NGF, p < 0.01 for all paired comparisons). Interestingly, 55% (6/11) of t(4;14) patients achieved MRD negativity, while only 12.5% (1/8) of patients with del17p were MRD negative.

Univariate and multivariate analyses

When the univariate analyses for PFS and OS were performed (Table 3), the MRD status detected by NGS and NGF were amongst the most statistically significant variables associated with the outcome: hazard ratios (HRs) for PFS according to the MRD status after transplantation were 0.20 for NGF (95% CI: 0.09–0.44, p < 0.001) and 0.29 for NGS (95% CI: 0.14–0.63, p = 0.002); HRs for OS were 0.18 for NGF (95% CI: 0.05–0.62, p = 0.007) and 0.21 for NGS (95% CI: 0.06–0.75, p = 0.02).

In the multivariate Cox regression models (Table 4), MRD negativity achieved by NGF (HR: 0.20, 95% CI: 0.09–0.45, p < 0.001) and the R-ISS I or II (HR: 0.37, 95% CI: 0.17–0.78, p = 0.01) were associated with the lowest risk of progression or death with independent value. Similarly, MRD negativity achieved by NGF was significantly associated with a decreased risk of death (HR: 0.21, 95% CI: 0.06–0.75, p = 0.02), along with the R-ISS (HR: 0.13, 95% CI: 0.05–0.38, p < 0.001). MRD negativity by NGS had similar results but it was removed from the stepwise analysis because of its close association with MRD by NGF. Nonetheless, when the analysis was done...
using the $10^{-5}$ cutoff, considering only the 95 patients not affected by preanalytical pitfalls, MRD negativity by NGF (HR: 0.16, 95% CI: 0.07–0.37, $p < 0.001$) and the R-ISS (HR: 0.30, 95% CI: 0.12–0.72, $p = 0.007$) were still selected for PFS, while MRD negativity by NGS (HR: 0.15, 95% CI: 0.04–0.57, $p = 0.005$) and the R-ISS (HR: 0.13, 95% CI: 0.04–0.39, $p < 0.001$) were selected for OS, indicating a similar potential for prediction.

**Discussion**

MRD evaluation has arisen as a very promising tool to predict the outcome of hematologic patients. On this behalf, the IMWG validated the use of this parameter to evaluate the deepest responses to treatment, measured either by flow or sequencing. Moreover, the FDA has recently cleared the use of NGS to perform MRD analyses. However, to date only one strategy has been approved (Adaptive’s clonoSEQ), which makes access difficult for many centers, and raises the need to find other suitable strategies. Here, we have evaluated and compared two different strategies: NGF, developed by the EuroFlow group and recommended by the IMWG, and the NGS-based LymphoTrack® IGH panel, a commercial strategy designed by Invivoscribe Technologies.

MRD results are highly dependent on the quality and concentration of the samples, which is directly related to
Table 4  Multivariate analysis for progression-free and overall survival.

| Variable               | Multivariate analysis for PFS | Multivariate analysis for OS |
|------------------------|-------------------------------|-----------------------------|
|                        | HR [95% CI]                  | HR [95% CI]                 |
| R-ISS stage            |                               |                             |
| I or II vs. III        | 0.37 [0.17–0.78]              | 0.13 [0.05–0.38]            |
| MRD status (NGF)       |                               |                             |
| Negative vs. positive  | 0.20 [0.09–0.45] <0.001       | 0.21 [0.06–0.74] 0.02       |
| MRD status (NGS)       |                               |                             |
| Negative vs. positive  | >0.05                         | >0.05                       |

Those variables with a significant impact in the univariate analysis were introduced in a multivariate Cox regression model to determine which were predictive for survival. Hazard ratios were calculated comparing first vs. second subgroup of each variable. Cytogenetics were included only as part of the R-ISS score. CI confidence interval, HR hazard ratio, MRD minimal residual disease, NGF next-generation flow, NGS next-generation sequencing, R-ISS revised international staging system.

Preanalytical conditions. Since flow cytometry requires an immediate experimental procedure, this is usually taken as a disadvantage compared to NGS, whose samples can be frozen and stored after gDNA extraction for later analyses. On the other hand, NGS relies on the identification of clonotypic rearrangements at diagnosis, making that up to 10% of cases cannot be followed due to somatic hypermutation in primer-annealing regions, though this was not the case in this study, and once it is characterized, CDR3 regions represent a stable and reliable tool for MRD evaluation. Other major flaws of NGS are the turnaround time, which is longer than for NGF (5–7 days compared to 24–48 h), and the need to run a high number of samples together. In contrast, interpretation of results is usually more difficult for NGF, requiring high expertise, while LymphoTrack’s solution is more user-friendly and semi-automated.

In our study, the use of ethanol precipitation resulted in suboptimal sample quantity, given that, in our experience, up to 40% of gDNA may be lost during its processing workflow, and the use of ethanol and sodium acetate usually turns to an increment of contaminating substances (salts and alcohol) that could interfere with PCR amplification. Accordingly, all the samples were optimal for NGF studies (criteria for inclusion), while 10% of the samples were suboptimal for NGS. If we had considered only optimal samples for both technologies, results would have favored NGS based on its slightly higher sensitivity using fewer cells; this represents a major advantage over NGF, that requires the acquisition of 10,000,000 events. However, all studies were done on an intention-to-study analysis, mimicking the intention-to-treat analysis that we usually see in clinical trials.

Despite being limited by the concentration method and the poor quality of certain samples, NGS was found to be fairly concordant with NGF in terms of MRD detection and quantification ability. Although we detected 15 discordant cases, only three of those patients relapsed (two positive cases by NGF, one positive case by NGS). In contrast, highly concordant results were observed in the MRD evaluation of the remaining 28 relapsing patients: 23 were double-positive and only five were negative by both methods, which could be explained by risk factors already present at diagnosis, extramedullary relapses, or infiltration levels below the limit of detection.

Most discordant cases had MRD levels below $10^{-5}$, that may be explained either by a higher sensitivity for one method over the other, or in the case of NGS, if technical inaccuracies due to the use of the spike in for quantification were present (i.e. underestimation of the MRD level). The only six discordant cases (NGS = 3; NGF = 3) with MRD levels over $10^{-5}$ could be explained based on differences in the sampling procedure (different tubes from different bone marrow pull), since sensitivity was set in the range of $10^{-5} – 10^{-6}$ for both techniques. Only three discordant cases relapsed, and accordingly no differences were seen with double-negative patients in terms of DFS, although an intermediate survival rate could be expected in a broader population with longer follow up.

According to the standard design of clinical trials, MRD is evaluated at several timepoints irrespective of the response. In our study, eight patients who had achieved VGPR as confirmed by immunofixation and electrophoresis had undetectable residual disease by next-generation techniques. This finding is concordant with a situation where tumor plasma cells had been eradicated in the bone marrow, while the monoclonal component was still present in the blood stream. Noteworthy, five of them achieved ≥CR after consolidation, supporting the notion that, in the clinical practice, MRD should be assessed whenever patients achieve CR.

Cytogenetic status still maintained its potential to stratify patients, but only when applied to the MRD-positive subset, a feature that has already been described for patients treated with the combination of bortezomib, lenalidomide, and dexamethasone. As far as this study is concerned, it seems that this treatment scheme could overcome the negative prognostic impact of t(4;14) and be able to provide MRD-negative responses. By contrast, 17p deletion still retained its association with poor survival rates, and was strongly correlated with MRD positivity.

Regarding the multivariate analysis, NGF retained a more independent informative capacity for survival than NGS because it was selected before in the multivariate...
analysis and the results of the two methods were closely associated. This result has to be interpreted with caution because the preanalytical conditions strongly affected NGS and could not be considered by the multivariate analysis. Despite that, NGS provided consistent and comparable results to NGF when only non-biased cases were evaluated.

As Perrot et al. have recently stated\(^{14}\), both NGF and NGS can reach a sensitivity of $10^{-6}$ when more cells are used and, in this context, the most important factor is not the technique but the ability to detect deeper levels of MRD, avoiding false-negative results due to lower detection limits. Direct comparison of MRD quantification by NGS and NGF in the same conditions (i.e. reaching the same sensitivity level and using the same marrow pull) should be performed to shed light into this issue, although an intrinsic false-negativity risk will always exist for both methodologies due to the patchy nature of the disease. As it was mentioned before, samples undergoing laboratory analysis are not the same, and a great variation can be detected from the first marrow pull (which is usually sent to the morphology laboratory) to the last one (which is distributed for molecular, cytogenetic, and immunophenotypic studies\(^{23,32}\). This could be a feasible explanation for the 15 discordant cases in our cohort. Nonetheless, our study demonstrates the similarity between NGS and NGF, with analogous results to those reported in the GEM2012 overall analysis of MRD by NGF\(^{30}\) but using ~10 times less cells.

In summary, our results support the use of the LympoTrack\textsuperscript{®} strategy to detect and evaluate MRD in MM patients, with excellent applicability and comparable results to NGF. Altogether, these findings reinforce the use of MRD assessment as an endpoint in MM clinical trials and underline the need of standardization and quality assessment in future studies for all MRD approaches in MM.

Acknowledgements
The authors wish to thank José Pérez, Alicia Antón, Rebeca Maldonado, Montserrat Hernández-Ruano, Estrella Arnés, Mercedes Jiménez, Alejandra Martín, Isabel Sánchez, Ana Balanzategui, Rocío Corral, and Francisco Boix (University Hospital of Salamanca, Spain) for their technical support, as well as the Spanish Multiple Myeloma GEM-PETHEMA group for providing clinical data. The authors are also very grateful to the patients who participated in this study.

Author details
1Departamento de Hematología, Hospital Universitario de Salamanca (HUSA/IBSAL), CIBERONC, OICR-BMCC (USAL-CSIC), Salamanca, Spain. 2Centro de Investigación del Cáncer-IBIMCC (USAL-CSIC), CIBERONC, Salamanca, Spain. 3Hospital Germans Trias i Pujol, Institut Català d’Oncologia (ICO), Institut Josep Carreras, Badalona, Spain. 4Hospital Clinic i Provincial, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 5Hospital Vall d’Hebron, Barcelona, Spain. 6Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. 7Hospital 12 de Octubre, i + 12, CNIO, Universidad Complutense, Madrid, Spain. 8Clinica Universidad de Navarra (CUN), Centro de Investigación Médica Aplicada, IDISNA, CIBERONC, Pamplona, Spain

Author contributions
AM, RG-S, NP, JF-M, and M. González conceived and designed the study. NP, NCG, AØ, LR, JB, M. Grionella, MTH, VG-C, JFSM, J-JL, M-VM, JM-L, M. González, and RG-S recruited patients for the Spanish Multiple Myeloma Working Group (GEM-PETHEMA) clinical trials. AM, CJ, MES, IP-C, and MG-A produced and analyzed the molecular results. NP, JF-M, MTC, BP, and AO produced and analyzed the immunophenotypic results. AM, MES, VG-C, and RG-S reviewed the data, performed the statistical analyses, and wrote the first draft of the manuscript. NP, JF-M, IP-C, MG-A, CC, MA, VG-C, and RG-S provided support for statistical analyses and clinical data interpretation. All the authors reviewed the final manuscript and agreed on its publication. RG-S and M. González obtained funding for the study. RG-S, the head of the group, produced the final revision of the manuscript and gave final approval for its publication.

Conflict of interest
The authors report grants P11/S101956, CIBERONC-CB16/12/00233, CE-2010-1-0010, FEHH, FI19/00320, IMS Young Investigator Award 2019, CP18/00028 and CB16/12/00400 during the conduct of the study. All Spanish funding is co-sponsored by the European Union FEDER program. N.P. has consulted for and has received honoraria from Janssen, Takeda, Amgen and Celgene. A.O. has consulted or served in an advisory role for Amgen, Celgene, Takeda and Janssen. L.R. has received honoraria from Celgene and Janssen. J.B. has received honoraria from Janssen. B.P. has received honoraria, consulted or served in an advisory role for Amgen, Bristol-Myers Squibb, Celgene, EngMab, Janssen, Merck, Novartis, Roche, Sanofi and Takeda. J.F.S. has consulted or served in an advisory role for Janssen, Celgene, Takeda, Amgen, BMS, MSD, Novartis, Sanofi, and Roche. J-JL has received honoraria from Amgen, Celgen, and Janssen. M-VM is on the board of directors or an advisory committee and has received honoraria from Janssen, Celgene, Takeda, Amgen, and BMS. J.M-L. has consulted or served in an advisory role for BMS, Janssen, and Novartis. RG-S has consulted for and received honoraria from Janssen, Takeda, BMS, Hospira, Pharmacies, Gilead, and Incyte. The remaining authors declare no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information
accompanies this paper at (https://doi.org/10.1038/s41408-020-00377-0).

Received: 23 July 2020 Revised: 14 September 2020 Accepted: 2 October 2020
Published online: 30 October 2020

References
1. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014).
2. Ocio, E. M. et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28, 525–542 (2014).
3. Goldschmidt, H., Ashcroft, J., Szabo, Z. & Garderet, L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann. Hematol. 98, 1–18 (2019).
4. Michael, J. et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. J. Clin. Oncol. 37, 1228–1263 (2019).
5. Lahuerta, J. J. et al. Busulfan 12.5mg/kg plus melphalan 140mg/m2 versus melphalan 200mg/m2 as conditioning regimen for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 95, 1913–1920 (2010).
6. Mateos, M. V. et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11, 934–941 (2010).
7. Rosinoí, L. et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood 134, 1337–1345 (2019).
8. Dure, B. G. et al. International uniform response criteria for multiple myeloma. *Leukemia* **20**, 1467–1473 (2006).
9. Mailankody, S. et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. *Natr. Rev. Clin. Oncol.* **12**, 286–295 (2015).
10. Landgren, O. & Owen, R. G. Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient. *Cytometry B* **90**, 14–20 (2016).
11. Paiva, B., García-Sanz, R. & San Miguel, J. F. Multiple myeloma minimal residual disease. *Cancer Treat Rev.* **169**, 103–122 (2016).
12. Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. *JAMA Oncol.* **3**, 28–35 (2017).
13. Lahuerta, J. J. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHMAGEM clinical trials. *J. Clin. Oncol.* **35**, 2900–10 (2017).
14. Perrot, A. et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. *Blood* **132**, 2456–2464 (2018).
15. Martínez-López, J. et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood* **123**, 3073–3079 (2014).
16. Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol.* **17**, e328–e346 (2016).
17. Paiva, B., Merino, J. & San Miguel, J. F. Utility of flow cytometry studies in the management of patients with multiple myeloma. *Curr. Opin. Oncol.* **28**, 511–517 (2016).
18. Ladetto, M. et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. *Leukemia* **28**, 1299–1307 (2014).
19. Cavo, M. et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncol.* **18**, e206–e217 (2017).
20. Stetler-Stevenson, M. et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. *Cytometry B* **90**, 26–30 (2016).
21. Mateos, M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N. Engl. J. Med.* **378**, 518–528 (2018).
22. Flores-Montero, J. et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. *Leukemia* **31**, 2094–2103 (2017).
23. Bai, Y., Orfao, A. & Chim, C. S. Molecular detection of minimal residual disease in multiple myeloma. *Br. J. Haematol.* **181**, 11–26 (2016).
24. Sarasquete, M. E. et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. *Haematologica* **90**, 1365–1372 (2005).
25. Puig, N. et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. *Leukemia* **28**, 391–397 (2014).
26. Chng, W. J. et al. IMWG consensus on risk stratification in multiple myeloma. *Leukemia* **28**, 269–277 (2014).
27. Palumbo, A. et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. *J. Clin. Oncol.* **33**, 2863–2869 (2015).
28. van Dongen, J. J. M. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMIHCT98-3956. *Leukemia* **17**, 2257–2317 (2003).
29. Puig, N. et al. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. *Leukemia* **29**, 1435–1437 (2015).
30. Paiva, B. et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. *J. Clin. Oncol.* **38**, 784–792 (2020).
31. Goicoechea, I. et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard and high risk myeloma. *Blood* 2020 Jul 21;blood.2020006751. [https://doi.org/10.1182/blood.2020006751](https://doi.org/10.1182/blood.2020006751) [Online ahead of print].
32. Rawstron, A. C. et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. *Haematologica* **93**, 431–438 (2008).